BC
KYMR icon

Bayforest Capital’s Kymera Therapeutics KYMR Stock Holding History

Bayforest Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
944
-600
-39% -$51.6K 0.1% 397
2026
Q1 		$129K Buy
+1,544
New +$122K 0.14% 281

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bayforest Capital's KYMR Position: Q2 2026 in Review

Bayforest Capital reduced its Kymera Therapeutics (KYMR) stake by 39% in Q2 2026, selling an estimated $51.6K and leaving 944 shares worth $108K. The position accounts for 0.1% of the portfolio, ranked #397.

Bayforest Capital first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. The position peaked at $129K in Q1 2026. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Bayforest Capital held 944 shares of Kymera Therapeutics worth $108K as of Q2 2026.
  • Bayforest Capital sold 600 Kymera Therapeutics shares in Q2 2026, an estimated $51.6K.
  • Kymera Therapeutics made up 0.1% of Bayforest Capital's portfolio in Q2 2026, its #397 holding.
  • Bayforest Capital first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bayforest Capital's Kymera Therapeutics position peaked at $129K in Q1 2026.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.